313392-22-2

Upstream product

• 38418-24-5 N-(4-bromophenyl)-3-oxobutyramide 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 17356-08-0 thiourea 

Downstream Products

• 1257437-66-3 4-bromophenyl 2-benzylsulfanyl-4-(2,4-dichlorophenyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 
• 1257437-69-6 4-bromophenyl 2-(4-chlorobenzylsulfanyl)-4-(2,4-dichlorophenyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 
• 1257437-67-4 4-bromophenyl 2-(2-chlorobenzylsulfanyl)-4-(2,4-dichlorophenyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 
• 1257437-68-5 4-bromophenyl 2-(3-chlorobenzylsulfanyl)-4-(2,4-dichlorophenyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 
• 1257437-70-9 4-bromophenyl 2-(4-fluorobenzylsulfanyl)-4-(2,4-dichlorophenyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide 

Relevant academic research and scientific papers

Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: Synthesis and pharmacological evaluation

A number of 5-(4-substituted phenyl)-2-(substituted benzylsulfanyl)-4- (substituted phenyl)-6-methyl-1,4-dihydro-5-pyrimidine carboxamides (1-30) were designed and synthesized keeping in view the structural requirements as suggested in the pharmacophore model for antihypertensive activity. All the synthesized compounds were tested for antihypertensive activity by non-invasive blood pressure (NIBP) measurements (tail-cuff method) in rats. Almost all the tested compounds displayed considerable decrease in the blood pressure as compared to control. Thirteen compounds showed significant antihypertensive activity comparable to the standard drug nifedipine.